FindTrial
Sign In

Certolizumab Pegol (CZP)

BIOLOGICAL6 trials

Sponsors

UCB Japan Co. Ltd., UCB Pharma, Nathan Wei, MD, FACP, FACR:, UCB Pharma SA, UCB BIOSCIENCES GmbH

Conditions

Crohn's DiseasePolyarticular-course Juvenile Idiopathic Arthritis (JIA)Rheumatoid Arthritis

Phase 2

Maintenance Study of Certolizumab Pegol (CZP) in Crohn's Disease
CompletedNCT00329550
UCB Japan Co. Ltd.Crohn's Disease
Start: 2006-05-31End: 2008-04-30Updated: 2015-03-18

Phase 3

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
CompletedNCT00717236
UCB PharmaRheumatoid Arthritis
Start: 2008-07-31End: 2011-03-31Updated: 2018-08-01
Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)
CompletedNCT01374971
Nathan Wei, MD, FACP, FACR:Rheumatoid Arthritis
Start: 2011-09-30End: 2012-07-31Updated: 2014-04-08
Pediatric Arthritis Study of Certolizumab Pegol
CompletedNCT01550003
UCB BIOSCIENCES GmbHPolyarticular-course Juvenile Idiopathic Arthritis (JIA)
Start: 2012-03-08End: 2024-04-08Updated: 2024-10-23

Phase 4

A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects
CompletedNCT01255761
UCB PharmaRheumatoid Arthritis
Start: 2010-11-30End: 2012-12-31Updated: 2018-07-31
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
CompletedNCT01500278
UCB Pharma SARheumatoid Arthritis
Start: 2011-12-31End: 2016-01-31Updated: 2018-07-31

Related Papers

Pharmacokinetics, effectiveness and safety of certolizumab pegol in children and adolescents with active juvenile idiopathic arthritis: 9+-year results from a multicenter, open-label study.
2026-07-13
Do high rheumatoid factor levels impact response to certolizumab pegol in patients with inadequately controlled rheumatoid arthritis? A post hoc analysis of the phase IIIb REALISTIC trial
RMD Open2026-01-01
Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis
Lara D. Veeken2024-09-0212 citations
P106 Do high rheumatoid factor titres impact response to tumour necrosis factor inhibitors? Comparison of certolizumab pegol and adalimumab in patients with rheumatoid arthritis and high titres of rheumatoid factor: a post hoc analysis of a phase 4 trial.
Lara D. Veeken2024-04-011 citations
Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post‐hoc analysis of clinical trials
International Journal of Rheumatic Diseases2023-05-1713 citations
A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial.
2017-09-2914 citations
Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
2016-11-15122 citations
Safety of Long-term Treatment With Certolizumab Pegol in Patients With Crohn's Disease, Based on a Pooled Analysis of Data From Clinical Trials.
2016-07-2517 citations
A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol.
2015-12-0119 citations
Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity.
2015-11-2713 citations
Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
2015-11-1515 citations
Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study.
2012-08-2591 citations